Zacks: argenx SE – American Depositary Shares (ARGX) Given $50.67 Average Price Target by Brokerages
argenx SE – American Depositary Shares (NASDAQ:ARGX) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus target price of $50.67 for the company and are predicting that the company will post ($0.38) earnings per share for the current quarter, according to Zacks. Zacks has also given argenx SE – American Depositary Shares an industry rank of 158 out of 265 based on the ratings given to its competitors.
Several research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of argenx SE – American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Companies raised their target price on shares of argenx SE – American Depositary Shares to $100.00 and gave the company an “overweight” rating in a research note on Tuesday, December 19th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $41.00 target price (up previously from $26.00) on shares of argenx SE – American Depositary Shares in a research note on Thursday, November 16th. They noted that the move was a valuation call.
Shares of argenx SE – American Depositary Shares (ARGX) traded down $2.64 during midday trading on Friday, hitting $59.79. 164,300 shares of the stock traded hands, compared to its average volume of 119,133. argenx SE – American Depositary Shares has a one year low of $17.33 and a one year high of $69.26.
TRADEMARK VIOLATION NOTICE: “Zacks: argenx SE – American Depositary Shares (ARGX) Given $50.67 Average Price Target by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/05/zacks-argenx-se-american-depositary-shares-argx-given-50-67-average-price-target-by-brokerages.html.
argenx SE – American Depositary Shares Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx SE - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.